TGA
Low-dose atropine EIKANCE secures first myopia TGA approval
The Therapeutic Goods Administration (TGA) has approved EIKANCE 0.01%, Australia’s first low-dose atropine eye drop for myopia progression in children ...
Prednefrin Forte supply to be reinstated in February 2022
Allergan has confirmed Prednefrin Forte (prednisolone acetate and phenylephrine hydrochloride) eye drops (10mL) will be available once again across Australian ...
Tasmanian centre joins race for CRISPR blindness cures
In 2016, at his home RANZCO scientific branch meeting in Tasmania, preeminent ophthalmic genetics expert Professor Alex Hewitt presented on ...
Glaukos announces TGA approval of late-stage glaucoma implant
Glaukos has secured Australian regulatory approval for the Preserflo MicroShunt, offering late-stage glaucoma patients a more elegant surgical alternative to ...
Prednefrin Forte shortage – TGA approves alternative product
Allergan has secured regulatory approval for an alternative product to address a Prednefrin Forte shortage in Australia. The company confirmed ...
Prednefrin Forte shortage: supplier working towards providing alternative
The Therapeutic Goods Administration (TGA) has confirmed a shortage of Prednefrin Forte 10mL eye drops in Australia, which isn't expected ...
Clinical trial results reinforce potential new treatment for DME
Novartis has announced positive findings from its the Phase 3 trial assessing the efficacy and safety of Beovu (brolucizumab) to ...
TGA approves Luxturna gene therapy
In a historical development for the eye health sector, the Therapeutics Goods Administration (TGA) has approved the country’s first true ...
TGA approves ‘breakthrough’ B+L contact lens
Bausch + Lomb has obtained regulatory approval to supply its new Ultra One Day daily disposable silicone hydrogel (SiHy daily) ...